DANA-FARBER CANCER INSTITUTE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1947-01-01

Employees: -

Market Cap: -

Website: http://www.dana-farber.org/

Clinical Trials

Sequential Angiogenic Blockade for the Treatment of Recurrent Mullerian Malignancies

Phase 2

Completed

Conditions: Ovarian Cancer
Peritoneal Cancer
Fallopian Tube Cancer

Interventions: Drug: Bevacizumab
Drug: Cyclophosphamide

First Posted Date: 2009-03-05

Last Posted Date: 2018-09-10

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 20

Registration Number: NCT00856180

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Letrozole in Women With Advanced Estrogen/Progesterone Receptor Positive Uterine Leiomyosarcoma

Phase 2

Completed

Conditions: Leiomyosarcoma

Interventions: Drug: letrozole

First Posted Date: 2009-03-05

Last Posted Date: 2017-04-18

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 27

Registration Number: NCT00856050

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Computerized Assessment for Patients With Cancer

Not Applicable

Completed

Conditions: Cancer

Interventions: Behavioral: Electronic Self-Report Assessment - Cancer (ESRA-C)

First Posted Date: 2009-02-27

Last Posted Date: 2018-02-01

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 779

Registration Number: NCT00852852

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
University of Washington Medical Center, Seattle, Washington, United States

Lung Cancer Symptom Assessment and Management Intervention

Phase 2

Completed

Conditions: Lung Cancer

Interventions: Behavioral: SAMI

First Posted Date: 2009-02-27

Last Posted Date: 2016-10-21

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 179

Registration Number: NCT00852462

Locations: 🇺🇸
Boston Medical Center, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

A Phase II Study of Epstein-Barr Virus-Specific Immunotherapy for Nasopharyngeal Carcinoma

Phase 2

Completed

Conditions: Nasopharyngeal Carcinoma

Interventions: Biological: Epstein-Barr Virus Specific Immunotherapy

First Posted Date: 2009-02-03

Last Posted Date: 2023-06-28

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 18

Registration Number: NCT00834093

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Prospective Analysis of Hypersensitivity Reactions to Oxaliplatin

Completed

Conditions: Colorectal Cancer
Small Bowel Cancer
Esophageal Cancer
Gastric Cancer
Pancreatic Cancer

First Posted Date: 2009-01-29

Last Posted Date: 2022-04-18

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 112

Registration Number: NCT00831571

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Bortezomib Plus Prednisone for Initial Therapy of Chronic Graft Versus Host Disease

Phase 2

Completed

Conditions: Chronic Graft Versus Host Disease

Interventions: Drug: bortezomib
Drug: Prednisone

First Posted Date: 2008-12-31

Last Posted Date: 2015-07-22

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 22

Registration Number: NCT00815919

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Collection and Banking of Leukemia Cells MDS/AML

Not Applicable

Completed

Conditions: Myelodysplastic Syndrome
Acute Myeloid Leukemia

Interventions: Other: Collection of Leukemia Cells

First Posted Date: 2008-12-17

Last Posted Date: 2013-02-07

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 90

Registration Number: NCT00809367

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Vaccination With Autologous, Lethally Irradiated Melanoma Cells Engineered by Adenoviral Mediated Gene Transfer to Secrete Granulocyte-Macrophage Stimulating Factor (GMSF)

Phase 1

Completed

Conditions: Melanoma

Interventions: Biological: Autologous, lethally irradiated melanoma cells

First Posted Date: 2008-12-17

Last Posted Date: 2024-08-21

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 84

Registration Number: NCT00809588

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Vaccination With GM-K562 Cells in Patients With Advanced Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) After Allogeneic Hematopoetic Stem Cell Transplantation

Phase 1

Completed

Conditions: Chronic Myelomonocytic Leukemia
Acute Myeloid Leukemia
Myelodysplastic Syndrome-Refractory Anemia With Excess Blasts

Interventions: Biological: GM-K562/leukemia cell vaccine

First Posted Date: 2008-12-17

Last Posted Date: 2020-09-16

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 33

Registration Number: NCT00809250

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy